OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Park on the FDA Vote Supporting Lumisight Use for Breast Cancer Detection During Surgery

March 9th 2024

Ko Un “Clara” Park, MD, discusses the FDA's vote in support of Lumisight for patients with breast cancer undergoing breast conserving surgery.

Dr Huppert on Data Informing the Sequence of Systemic Therapy in Early-Stage TNBC

March 9th 2024

Laura A. Huppert, MD, discusses data informing the sequence of immunotherapy and chemotherapy regimens in early-stage triple-negative breast cancer.

Dr Smith on the Value of Mentorship in Oncology

March 8th 2024

Sonali M. Smith, MD, discusses the value of mentorship in oncology practice on International Women’s Day.

Dr Möller on Gender Biases in Oncology

March 8th 2024

Mecker G. Möller, MD, discusses the importance of addressing gender biases in oncology.

Dr Miller on the Importance of Patient Advocacy in Gynecologic Oncology

March 8th 2024

Eirwen M. Miller, MD, discusses the importance of advocating for women in gynecologic oncology on International Women’s Day.

Dr Litton on Navigating the Sequencing of PARP Inhibitors in Early-Stage TNBC

March 8th 2024

Jennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.

Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast Cancer

March 8th 2024

Kevin Kalinsky, MD, MS, discusses questions regarding the utility and implementation of genomic testing approaches in hormone receptor–positive breast cancer.

Dr Coopey on Institutional and Societal Initiatives to Support Women in Oncology

March 8th 2024

Suzanne B. Coopey, MD, FACS, discusses ways that women in oncology can feel further supported and advocated for in the cancer care space.

Dr Coopey on Addressing Gender Disparities in Cancer Care

March 8th 2024

Suzanne B. Coopey, MD, FACS, discusses the importance of addressing gender disparities in cancer care.

Dr Ailawadhi on Early Data for Iopofosine I 131 in Waldenström Macroglobulinemia

March 8th 2024

Sikander Ailawadhi, MD, discusses early efficacy and safety data for iopofosine I 131 monotherapy in Waldenström macroglobulinemia.

Dr Phillips on Efforts to Clarify and Refine Management Approaches in Relapsed/Refractory MCL

March 7th 2024

Tycel Phillips, MD, discusses efforts to clarify and refine the treatment paradigm of patients with mantle cell lymphoma.

Dr Mamounas on Key Advancements in the Use of Locoregional Therapy in Breast Cancer

March 7th 2024

Terry P. Mamounas, MD, discusses key advancements in the use of locoregional therapy for patients with breast cancer.

Dr Gopal on the Nuances of IO/TKI Selection in Advanced RCC

March 7th 2024

Nikhil A. Gopal, MD, discusses the nuances of treatment decision-making in advanced renal cell carcinoma.

Dr Gopal on the Evolution of TKI/IO Combination Approaches in RCC

March 7th 2024

Nikhil A. Gopal, MD, discusses the transition of treatment with TKIs to treatment with TKI/IO combinations for those with renal cell carcinoma.

Dr Alvarado on Selecting Breast Conservation Surgery vs Mastectomy After Neoadjuvant Therapy

March 7th 2024

Michael D. Alvarado, MD, discusses the decision to undergo breast conservation surgery vs mastectomy following neoadjuvant breast cancer therapy.

Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting

March 7th 2024

Ajai Chari, MD, discusses the 2024 OncLive® Bridging the Gaps in Hematologic Malignancies meeting, highlighting the treatment of multiple myeloma.

Dr Wander on the ELAINE Trial Portfolio of Lasofoxifene in ER+/HER2– Breast Cancer

March 6th 2024

Seth Wander, MD, PhD, discusses the ELAINE-1, ELAINE-2, and ELAINE-3 trials in patients with ER-positive, HER2-negative metastatic breast cancer.

Dr Childs on Treatment With Olaparib Plus Abiraterone in mCRPC

March 6th 2024

Dan S. Childs, MD, discusses treatment with olaparib and abiraterone in metastatic castration-resistant prostate cancer.

Dr Park on the Sequencing of Treatment Options in Metastatic Urothelial Cancer

March 6th 2024

Chandler H. Park, MD, FACP, discusses the implications of the phase 2 TROPHY-U-01 trial in metastatic urothelial carcinoma.

Dr Moustafa on the Evolving Use of Bispecific Antibodies in DLBCL

March 6th 2024

Muhamad Alhaj Moustafa, MD, MS, discusses the evolution of bispecific antibodies in diffuse large B-cell lymphoma.